Group 1 - The company announced adjustments to the fundraising amounts for certain clinical trial sub-projects within its "Innovative Drug R&D Project" while keeping the total fundraising amount unchanged [1][2] - New sub-projects such as "JS207 domestic and overseas R&D," "JS107 domestic and overseas R&D," and "JS125 domestic and overseas R&D" have been added, while funding for several other drug developments has been reduced [1] - JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody developed by the company, primarily for the treatment of advanced malignancies, currently in Phase II clinical trials [1] Group 2 - The adjustments in fundraising project sub-items and amounts are based on the company's development strategy and product R&D progress, aimed at improving fundraising efficiency and optimizing resource allocation [2] - The changes are expected to provide financial support for the company's product development and contribute to its long-term growth [2]

Core Viewpoint - BeiGene has decided to terminate the clinical development of its TIGIT inhibitor, ociperlimab, after an independent data monitoring committee recommended stopping the ongoing Phase III AdvanTIG-302 trial due to the likelihood of not meeting the primary endpoint of overall survival [1][2]. Group 1: Company Actions - BeiGene has invested a total of 2.09 billion RMB (approximately 20.9 million) in the ociperlimab project as of the first half of 2024 [1][2]. - The decision to terminate the trial was made after careful consideration of the efficacy and safety data, with no new safety signals identified [2]. - Following the termination of the trial, BeiGene will focus its resources on more promising candidates with clinical differentiation [2]. Group 2: Collaboration and Financials - In December 2021, BeiGene entered into an option agreement with Novartis, granting Novartis exclusive rights to develop, manufacture, and commercialize ociperlimab, for which BeiGene received a $300 million upfront payment [3]. - In July 2024, BeiGene and Novartis signed a termination agreement, allowing BeiGene to regain all global rights to ociperlimab [3]. - As of the end of 2023, BeiGene reported collaboration revenue related to the ociperlimab agreement of $192 million (approximately 1.41 billion RMB), which is expected to decrease to $18.26 million (approximately 134 million RMB) by the end of 2024 [4]. Group 3: Industry Context - The TIGIT pathway has been a popular target in cancer treatment development, with multiple pharmaceutical companies, including Roche, Bristol-Myers Squibb, and Merck, also halting their TIGIT antibody research due to unsatisfactory results [5][6]. - Despite the setbacks, some companies, such as AstraZeneca and GSK, continue to pursue TIGIT-related therapies, with ongoing clinical trials for their respective candidates [6].